Venmax Drugs Board Approves Hatri Pharma Merger Amendments

Venmax Drugs and Pharmaceuticals Limited's amended issued, subscribed, and paid-up share capital stands at Rs. 11,58,29,300 (1,15,82,930 equity shares of Rs. 10 each). The company also amended 36,81,000 convertible equity share warrants pending allotment, valued at Rs. 5 each.

Key Amendments Approved

The Board of Directors of Venmax Drugs and Pharmaceuticals Limited met on March 27, 2026, to approve significant amendments to the draft Scheme of Amalgamation with Hatri Pharma Private Limited. The core changes focus on the Share Capital Clause, specifically revising the issued, subscribed, and paid-up capital of Venmax. Amendments also cover the status of convertible equity share warrants.

Strategic Benefits of the Merger

This strategic move is designed to unlock benefits from combining operations and enhance business efficiency. The amalgamation aims to create a fully integrated business model, optimize resource allocation, and streamline compliance functions by consolidating both companies into a single listed entity.

Background of the Deal

Venmax Drugs and Pharmaceuticals Limited is an Indian company engaged in manufacturing pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company is pursuing this amalgamation with Hatri Pharma Private Limited to combine their operations in the competitive pharmaceutical landscape. Hatri Pharma Private Limited is an ISO 9001:2015 certified company with a manufacturing facility in SPSR Nellore District, Andhra Pradesh, India, commencing operations in 2022.

The initial approval of the amalgamation was granted on September 2, 2025, with the Board of Directors approving financial statements as of September 30, 2025, for valuation purposes. The amalgamation involves a 1:1 share exchange ratio, where shareholders of Hatri Pharma will receive 1 equity share of Venmax for every 1 share held.

Key Changes from Amendments

• Shareholders of Hatri Pharma will receive 1 Equity Share of Venmax for every 1 Equity Share they hold.
• The financial structure of Venmax will reflect the amended share capital and warrant position.
• Operational integration aims for cost efficiencies and margin improvement post-amalgamation.
• Unified administrative and compliance functions will reduce overheads.

Regulatory Hurdles Ahead

The amalgamation scheme's finalization is contingent on obtaining necessary approvals from the Central Government and the National Company Law Tribunal (NCLT).

A requisite majority vote from public shareholders is also a critical condition for the scheme's sanction.

Failure to secure these approvals could render the scheme null and void.

Market Context

While Venmax and Hatri Pharma merge, major players like Sun Pharmaceutical Industries, Cipla, and Dr. Reddy's continue to expand their market presence. These peers operate with significant scale and diversified product portfolios, setting a high bar for the combined company.

Looking Ahead

• Monitor the progress and timelines for NCLT and Central Government approvals.
• Observe the outcome of the shareholder voting process on the revised amalgamation scheme.
• Track any further announcements regarding the integration timeline and operational synergy realization.